News

  • 18 December 2011

    AstraZeneca’s Faslodex given final snub by NICE

    The UK's National Institute for Health and Clinical Excellence (NICE) has snubbed AstraZeneca breast cancer drug Faslodex in its final guidance, deeming it an inefficient use of NHS resources.

  • 14 December 2011

    UK cancer treatment costs to spiral by 2021

    The costs associated with the diagnosis and treatment of cancer in the UK will dramatically increase by 2021, according to a new report published by private healthcare provider Bupa.

  • 13 December 2011

    GSK subsidiary charged with fraud

    Stiefel Laboratories, a subsidiary of GlaxoSmithKline, has been charged with fraud by the US Securities and Exchange Commission (SEC) after stock was repurchased at severely undervalued prices.

  • 12 December 2011

    Glenmark to seek Napo arbitration

    Glenmark Pharmaceuticals has said that it will seek an arbitration in the US following the termination of an agreement with Napo Pharmaceuticals, with Glenmark claiming there was no basis for...

Go Top